Javascript must be enabled to continue!
IMPROVED STREPTOKINASE PRODUCTION
View through CrossRef
Several strains of beta-hemolytic Streptococci produce streptokinase enzymethat can bind and activate human plasminogen to plasmin. Streptokinase degrades the fibrinlump by its explicit lysine joining site and so it is applied as a remedy in thrombolytic therapy.The purpose of the study was to subject wild strain of Streptococcus equisimilis to straindevelopment technique, using random mutagenesis by UV irradiation for enhanced productionof streptokinase. Objective: To evaluate the hyper production of streptokinase after mutagenesisof wild Streptococcus equisimilis by means of UV irradiation. Study Design: Randomized study.Period: 2012-2014. Setting: Enzyme Biotechnology Laboratory, Department of Biochemistry,University of Agriculture, Faisalabad-Pakistan. Materials and Methods: UV lamp (TUP 40wlamp which has about 90% of its radiation at 2540-2550 A0) was used for the mutation ofStreptococcus equisimilis cells (1x 107 cells mL-1) for enhanced production of streptokinase. 10mL fresh inoculum was transferred to sterile petri plates, which were exposed to UV light for 30,60, 90, 120, 150, 180, 210, 240 and 270 minutes. The exposure was carried out at distance of20cm from the centre of lamp. A dose producing 87% killing was selected as optimum dose,after preparing kill curve. The kill/ survival curve was prepared and time of exposure giving(210 minutes) 3 log kill was selected for mutation of the Streptococcus equisimilis for hyperproduction of streptokinase enzyme. Results: Enzyme assay was performed for both wildand mutant strains. Dose of 210 minutes was selected as best dose which was followed bythe selection using triton X-100. Finally the selected strain S. equisimilis EBL-UV-210 showed480 U mL-1 of streptokinase activity in quantitative blood clot liquefaction test, which is quitehigher than wild strain (370 U mL-1). This maximum yield of streptokinase was obtained after24h, at CSL 4%, pH 7.5, 37oC, KH2PO4 0.04%, K2HPO4 0.05%, MgSO4. 7H2O 0.04%, NaHCO30.15%, CaCO3 0.004%, CH3COONa. 3H2O 0.10%, FeSO4. 7H2O 0.04%, MnCl2. 4H2O 0.02%,glucose 2%, yeast extract 3% and 5% inoculum size in liquid state fermentation. Conclusions:Results showed that mutated strain gave enhanced streptokinase activity in comparison tothe wild strain. Our current study focused on streptokinase production from this UV mutatedstreptococcus equisimilis species and purification of this enzyme by ammonium sulfateprecipitation, Ion exchange and gel filtration chromatography. The activity of streptokinase wasdetermined by using quantitative blood clot liquefaction method.
Independent Medical Trust
Title: IMPROVED STREPTOKINASE PRODUCTION
Description:
Several strains of beta-hemolytic Streptococci produce streptokinase enzymethat can bind and activate human plasminogen to plasmin.
Streptokinase degrades the fibrinlump by its explicit lysine joining site and so it is applied as a remedy in thrombolytic therapy.
The purpose of the study was to subject wild strain of Streptococcus equisimilis to straindevelopment technique, using random mutagenesis by UV irradiation for enhanced productionof streptokinase.
Objective: To evaluate the hyper production of streptokinase after mutagenesisof wild Streptococcus equisimilis by means of UV irradiation.
Study Design: Randomized study.
Period: 2012-2014.
Setting: Enzyme Biotechnology Laboratory, Department of Biochemistry,University of Agriculture, Faisalabad-Pakistan.
Materials and Methods: UV lamp (TUP 40wlamp which has about 90% of its radiation at 2540-2550 A0) was used for the mutation ofStreptococcus equisimilis cells (1x 107 cells mL-1) for enhanced production of streptokinase.
10mL fresh inoculum was transferred to sterile petri plates, which were exposed to UV light for 30,60, 90, 120, 150, 180, 210, 240 and 270 minutes.
The exposure was carried out at distance of20cm from the centre of lamp.
A dose producing 87% killing was selected as optimum dose,after preparing kill curve.
The kill/ survival curve was prepared and time of exposure giving(210 minutes) 3 log kill was selected for mutation of the Streptococcus equisimilis for hyperproduction of streptokinase enzyme.
Results: Enzyme assay was performed for both wildand mutant strains.
Dose of 210 minutes was selected as best dose which was followed bythe selection using triton X-100.
Finally the selected strain S.
equisimilis EBL-UV-210 showed480 U mL-1 of streptokinase activity in quantitative blood clot liquefaction test, which is quitehigher than wild strain (370 U mL-1).
This maximum yield of streptokinase was obtained after24h, at CSL 4%, pH 7.
5, 37oC, KH2PO4 0.
04%, K2HPO4 0.
05%, MgSO4.
7H2O 0.
04%, NaHCO30.
15%, CaCO3 0.
004%, CH3COONa.
3H2O 0.
10%, FeSO4.
7H2O 0.
04%, MnCl2.
4H2O 0.
02%,glucose 2%, yeast extract 3% and 5% inoculum size in liquid state fermentation.
Conclusions:Results showed that mutated strain gave enhanced streptokinase activity in comparison tothe wild strain.
Our current study focused on streptokinase production from this UV mutatedstreptococcus equisimilis species and purification of this enzyme by ammonium sulfateprecipitation, Ion exchange and gel filtration chromatography.
The activity of streptokinase wasdetermined by using quantitative blood clot liquefaction method.
Related Results
A Comparative Study to Assess the Efficacy of Streptokinase in Diabetic Versus Non-Diabetic Acute ST Elevation Myocardial Infarction Patients
A Comparative Study to Assess the Efficacy of Streptokinase in Diabetic Versus Non-Diabetic Acute ST Elevation Myocardial Infarction Patients
Objective: Prominent resolution in the ST segment elevation on electrocardiogram(ECG), thrombolysis at the infarction site restoring perfusion determines the effectiveness of the s...
Frequency of hypotension after intravenous streptokinase in patients presenting with ST elevation myocardial infarction
Frequency of hypotension after intravenous streptokinase in patients presenting with ST elevation myocardial infarction
INTRODUCTION: One of the primary causes of death and disability worldwide is Acute Myocardial Infarction. Streptokinase is still widely used in many countries for its treatment, de...
Association of Increased Neutrophil to Lymphocyte Ratio to in-Hospital Outcome of Acute anterior Myocardial Infarction Patients Subjected to Thrombolytic Therapy with Streptokinase
Association of Increased Neutrophil to Lymphocyte Ratio to in-Hospital Outcome of Acute anterior Myocardial Infarction Patients Subjected to Thrombolytic Therapy with Streptokinase
Background: Myocardial infarction mainly contributes to morbidity and mortality around the globe. Thrombolytic therapy with streptokinase is the primary treatment strategy for pati...
Systemic Streptokinase Infusion for Declotting of Hemodialysis Arteriovenous Fistulas
Systemic Streptokinase Infusion for Declotting of Hemodialysis Arteriovenous Fistulas
In 17 out of 29 hospitalized patients (58.6%) with internal arteriovenous fistula (AVF) thrombosis a systemic streptokinase infusion was used as an alternative to urgent surgical d...
Immunomodulatory Activity of Staphylococcus aureus Purified Staphylokinase and Streptokinase in BALB/C mice
Immunomodulatory Activity of Staphylococcus aureus Purified Staphylokinase and Streptokinase in BALB/C mice
This experimental in vivo purpose of this study was to look into the immunomodulatory effects of purified staphylokinase produced by local clinical Staphylococcus aureus isolates c...
Thrombolytic Treatment During Pregnancy
Thrombolytic Treatment During Pregnancy
The treatment of occlusive deep vein thrombosis during pregnancy with fibrinolytic agents as streptokinase and urokinase is still controversial. The main points of controversy are ...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Pulmonary haemorrhage following thrombolysis with streptokinase in myocardial infarction
Pulmonary haemorrhage following thrombolysis with streptokinase in myocardial infarction
Pulmonary haemorrhage is a rare but a life-threatening complication of thrombolytic therapy in patients with acute ST-elevation myocardial infarction (MI). It usually presents with...

